- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Dermatology Life Quality Indexprovides different information from PASI
Washington - The Dermatology Life Quality Index (DLQI) is a widely used and validated measure of patient-reported outcomes in psoriasis. Unlike the Psoriasis Area Severity Index (PASI) score, a well-established measure of a patient's disease activity where each area of the body is weighted proportionally to the surface area covered, the DLQI is more heavily influenced by areas of the body that are readily visible, such as the head and lower extremities. "Therefore, the DLQI may provide information regarding outcomes beyond that described by the PASI score," said Alexa B. Kimball, M.D., M.P.H., assistant professor of dermatology at Stanford University.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
